16 results about "Bladder Tissue" patented technology

The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

The application provides a urine exosome-based bladder cancer gene detection system and application, and relates to the technical field of biological detection. Through the cooperative application of the internal reference gene and the diagnosis model, the application provides a reliable endogenous quality control standard for the bladder tissue-derived exosome in the urine exosome sample; meanwhile, the application realizes non-invasive, accurate, rapid screening, diagnosis, prognosis and recurrence monitoring of bladder cancer, lays a key technical foundation and detection tool for the urine exosome-based molecular diagnosis of bladder cancer, and has important clinical transformation value and application prospect.

Provided herein are materials and methods related to scaffolds and uses thereof. In some embodiments, provided herein are poly (octamethylene-octanol citrates) (POOC) scaffolds with native mechanical properties that are comparable to urinary bladder tissue. In some embodiments, provided herein are methods for the synthesis of POOC scaffolds with native mechanical properties that are comparable to urinary bladder tissue by including octanol in the polycondensation synthesis of POC. In some embodiments, provided herein are methods of use of the disclosed scaffolds, including for urinary bladder tissue regeneration.

The need for improved drug delivery methods and systems for treating bladder cancer remains. It exists as such. [Solution] Gemcitabine is administered intravesically into the bladder of patients requiring treatment for bladder cancer, and then absorbed into the bladder tissue. A sustained concentration of gemcitabine sufficient to produce the above-mentioned therapeutically effective concentration By obtaining mucitabine in the urine of the bladder, the above patients can be administered gemcitabine. A drug delivery device and method are provided. In an embodiment, local delivery into the bladder of the patient. The administration is based on the average dose of gemcitabine (FBE) mentioned above, ranging from 1 mg / day to approximately 300 mg / day. That is the case.

The invention relates to the technical field of genes and medical engineering, in particular to an escherichia coli targeted culture method, and further discloses application of the escherichia coli targeted culture method in the field of mucosa repair. According to the Escherichia coli targeted culture method, in order to improve the colonization ability of EcN to damaged bladder tissue, the adhesive EcN is selected through a bacterial binding and culture (BBC) strategy inspired by further bacterial domestication, so that the adhesive EcN specifically bound with inflammatory bladder epithelial cells is screened, and the specific binding capacity of the EcN to the damaged bladder tissue is improved. The EcN can target and colonize inflammatory bladder tissue for a long time through one-time therapy.

The present application relates to the field of biotechnology, in particular to human bladder tissue digestion solution and application thereof.The digestion method of the present application can dissociate human bladder tissue cells while keeping the cell viability at more than 90%, and the amount of harvested cells is also obviously improved.Sufficient cell amount is the prerequisite for optimization treatment such as red blood cell lysis and dead cell removal.The single cell suspension obtained by the method has high viability, low clumping rate, high nucleated rate and less impurities, which can provide a basis for obtaining high-quality gene expression data in human bladder tissue single cell sequencing experiment.The present application can quickly obtain human bladder tissue primary cell suspension (sufficient cell amount, high viability, low clumping rate and less impurities) meeting the requirements of single cell experiment within 2-4 hours.

The invention relates to the use of epidermal growth factor for the manufacture of a medicament for the treatment of interstitial cystitis. The "epidermal growth factor" (EGF) of the invention can be used to manufacture an excellent medicament for interstitial cystitis. The medicament has a composition that includes an active ingredient, adjuvant, dispersant, wetting agent, and / or suspension agent. The carrier of the epidermal growth factor is water, colloid, hyaluronic acid, natural oils, and / or glucose. The medicament serves to reduce urinary frequency. The medicament serves to restore bladder elasticity. The medicament serves to reduce cystitis. The medicament serves to increase the antioxidant capacity in bladder tissue.The present invention proposes a novel effect of epidermal growth factor, which can be used to treat interstitial cystitis and to repair the bladder mucosa and exhibits excellent efficacy.

The invention belongs to the technical field of biological medicine and molecular biology, and provides application of S100A8 in preparation of a medicine for preventing / treating bladder infection after spinal cord injury. The S100A8 can be used as a prevention target of bladder infection after potential spinal cord injury, and after the S100A8 is perfused into the bladder, the colony count of the bladder tissue is obviously reduced, so that the S100A8 has an infection prevention effect; meanwhile, the damage repair capacity of the bladder epithelium is remarkably improved, the compound can be used as a prevention / treatment target spot for preventing bladder infection after spinal cord injury, and a new thought is provided for clinical prevention and treatment of bladder infection after spinal cord injury.

The invention provides a method of treating interstitial cystitis that applies therapeutic exomes to the bladder of a patient through intravesical administration. Unlike the intravesical administration of stem cells, the intravesical administration of exosomes permits a therapeutic amount of paracrine-active growth factors and cytokines to be applied to bladder tissue before they can voided by urination.

Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of bladder cancer treatment by intravesical administration of gemcitabine into the patient's bladder to achieve a sustained urinary concentration of gemcitabine in the bladder sufficient to produce a therapeutically effective concentration of gemcitabine in the bladder tissues. In embodiments, the local administration into the patient's bladder is in an average amount of from 1 mg / day to about 300 mg / day of gemcitabine (FBE).

The application provides a urine exosome-based bladder cancer gene detection system and application, and relates to the technical field of biological detection. Through the cooperative application of the internal reference gene and the diagnosis model, the application provides a reliable endogenous quality control standard for the bladder tissue-derived exosome in the urine exosome sample; meanwhile, the application realizes non-invasive, accurate, rapid screening, diagnosis, prognosis and recurrence monitoring of bladder cancer, lays a key technical foundation and detection tool for the urine exosome-based molecular diagnosis of bladder cancer, and has important clinical transformation value and application prospect.

Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg / day to about 300 mg / day of the gemcitabine (FBE).

Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg / day to about 300 mg / day of the gemcitabine (FBE).

The invention belongs to the technical field of exosome application, and discloses a triptolide-loaded nano co-delivery drug delivery carrier and application thereof in preparation of drugs for treating interstitial cystitis. The triptolide-loaded nano co-delivery drug delivery carrier is used for interstitial cystitis model animals, and the following changes are observed: 1, the sensitivity of the model animals to stimulation is reduced; 2, the urination frequency of model animals is reduced, and the urination volume of words is increased; 3, the number of red blood cells in urine of the model animal is reduced; 4, bladder tissue hyperemia is relieved, and the size is reduced; and 5, the expression of inflammatory factors IL-6, MCP-1, ICAM-1 and BAX is obviously reduced. Therefore, it can be determined that the triptolide-loaded nano-co-delivery drug delivery carrier is used for treating interstitial cystitis. According to the research, the application range of the triptolide is expanded, and the triptolide is combined with the exosome to be used for treating the interstitial cystitis, so that a new thought is provided for treating the interstitial cystitis.

Devices and methods for delivering treatment fluids or particulates such as, stem cells, drugs, Botox and like, to an inner lining of a bladder for treatment of urinary tract disorders, including over-active bladder. A balloon delivery system can include an inflation balloon having a plurality of micro-needles configured to pierce and otherwise puncture an inner bladder wall so as to deliver the treatment fluid to bladder tissue. The treatment fluid can be directly injected into the bladder tissue using the micro needles. Alternatively, the micro needles can be fabricated of bioabsorbable or bioresorbable materials such that the micro needles can remain embedded within the bladder tissue to deliver the treatment fluid or particulate.

The invention discloses a mouse reversible ureteral obstruction model and a construction method thereof, and the construction method comprises the following steps: carrying out anesthesia treatment on a mouse, fixing the supine position of the mouse, and carrying out skin preparation disinfection; cutting the middle of the lower abdomen of the mouse, removing the bladder out of the body, and exposing a ureter area and the joint of the lower end of the free ureter and the ureter bladder; the bladder tissue below the ureter bladder connecting position is ligated; sewing and closing abdominal muscles and skin by adopting a suture line; according to the construction method disclosed by the invention, through setting of a specific construction method, an obstruction region can be formed in a mouse bladder region, and the ureter cannot be obviously damaged, so that the obstruction success rate of the model can reach 100%, and the success rate of a recanalization operation can reach 90% or above.